We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Oral Specimen Collection Device Developed for High-Throughput Laboratories

By Labmedica staff writers
Posted on 20 Feb 2008
Print article
An oral fluid-sample device is used to collect high-quality oral fluid specimens for high-throughput laboratory testing.

The Aware Messenger oral fluid-sample collection device uses an untreated, soft, tasteless swab and takes only 15-20 seconds to collect a sample rich in oral mucosal transudate. The device yields a large quantity of sample that is ready for testing without additional processing by the testing laboratory, either immediately upon receipt, or later at a remote testing laboratory. Unlike other oral fluid collection devices, the swab contains no salts, animal proteins, or other additives that can interfere with assays or cause an adverse taste. Additionally, the sample buffer used in the system is formulated with immunoassay friendly components at appropriate levels facilitating assay optimization and improving performance.

Collecting a sample with the Aware Messenger device involves a simple back and forth wipe of the upper and lower gum line with a swab, which is then placed into a buffer tube. The swab is expressed into the tube and discarded immediately after use. The tube containing the sample can then be delivered to the laboratory where the sample can be immediately and directly used in a suitably validated assay without processing, or stored for batch testing later.

The Aware Messenger oral fluid collection system is derived from the collection system developed for Calypte Biochemical Corp.'s (Portland, OR, USA) Aware human immunodeficiency virus (HIV)-1/2 rapid test where it has been extensively field tested and demonstrated its capability to consistently collect a quality, IgG-rich oral fluid sample.

"We developed the Aware Messenger device in response to inquiries from several of our U.S. and international customers who requested a safe, simple, and cost-effective alternative to currently marketed sampling devices. In addition, the device will meet the sample collection needs of potential customers who are seeking an alternative to blood testing but still prefer the advantages of high volume batch testing provided by traditional diagnostic methods such as [enzyme immunoassay] EIA,” stated Roger I. Gale, Calypte's president and CEO.

The current device is generic, and it will require user validation for each individual application for diagnostic use by the laboratory. A constantly growing body of literature supports the use of oral fluid specimens as an accurate alternative to blood for the testing for antibodies, antigens, drugs, and genetic testing.

Calypte Biomedical is a healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases that are suitable for use at the point-of-care and at home. The company believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries lacking the medical infrastructure to support laboratory-based testing.


Related Links:
Calypte
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Entamoeba Test
RIDASCREEN Entamoeba Test
New
Adenovirus Test
S3334E ADV Adenovirus Kit

Print article

Channels

Microbiology

view channel
Image: Genetic testing can determine which drugs will work for patients with C. auris (Photo courtesy of Shutterstock)

Genetic Testing Could Improve Treatment for Virulent Multidrug-Resistant Fungus Candida Auris

Candida auris (C. auris), a multidrug-resistant yeast responsible for severe, life-threatening infections, was first identified in 2009. Since its discovery, it has spread globally, causing significant... Read more

Pathology

view channel
Image: The unique AI tool predicts cancer prognoses and responses to treatment (Photo courtesy of Shutterstock)

AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.